SYNLOGIC, INC. Increase (Decrease) in Contract with Customer, Liability
SYNLOGIC, INC. (SYBX) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-03-06
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00.
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00.
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was $0.00.
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$882.00K, a 351.28% decline from fiscal 2022.
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $351.00K, a 33.90% decline from fiscal 2021.
- SYNLOGIC, INC. increase (decrease) in contract with customer, liability for fiscal 2021 was $531.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | -$264.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | -$264.00K derived: sum of 3 quarters · filed 2025-03-06 | -$657.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | -$264.00K derived: sum of 2 quarters · filed 2025-03-06 | -$657.00K derived: sum of 3 quarters · filed 2025-03-06 | -$692.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | -$264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$657.00K derived: sum of 2 quarters · filed 2025-03-06 | -$692.00K derived: sum of 3 quarters · filed 2025-03-06 | -$882.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | -$393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$428.00K derived: sum of 2 quarters · filed 2024-11-12 | -$618.00K 10-Q · filed 2024-11-12 | -$707.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$225.00K 10-Q · filed 2024-08-08 | -$314.00K derived: sum of 3 quarters · filed 2024-08-08 | $508.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$190.00K 10-Q · filed 2024-05-14 | -$279.00K derived: sum of 2 quarters · filed 2024-05-14 | $543.00K derived: sum of 3 quarters · filed 2024-05-14 | $378.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $733.00K derived: sum of 2 quarters · filed 2024-03-19 | $568.00K derived: sum of 3 quarters · filed 2024-03-19 | $351.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $822.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $657.00K derived: sum of 2 quarters · filed 2023-11-09 | $440.00K 10-Q · filed 2023-11-09 | -$17.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$382.00K 10-Q · filed 2023-08-10 | -$839.00K derived: sum of 3 quarters · filed 2023-08-10 | -$755.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$217.00K 10-Q · filed 2023-05-11 | -$674.00K derived: sum of 2 quarters · filed 2023-05-11 | -$590.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$373.00K derived: sum of 2 quarters · filed 2023-03-29 | $531.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $988.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $904.00K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | -$444.00K derived: sum of 3 quarters · filed 2022-03-17 | -$544.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$444.00K derived: sum of 2 quarters · filed 2021-11-10 | -$544.00K 10-Q · filed 2021-11-10 | -$1.77M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$444.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$544.00K 10-Q · filed 2021-08-12 | -$1.77M derived: sum of 3 quarters · filed 2021-08-12 | -$2.08M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$100.00K 10-Q · filed 2021-05-13 | -$1.33M derived: sum of 2 quarters · filed 2021-05-13 | -$1.64M derived: sum of 3 quarters · filed 2021-05-13 | -$1.99M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.54M derived: sum of 2 quarters · filed 2021-03-25 | -$1.89M derived: sum of 3 quarters · filed 2021-03-25 | $276.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | -$305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$654.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.51M 10-Q · filed 2020-11-05 | $1.40M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.81M 10-Q · filed 2020-08-06 | $1.70M derived: sum of 3 quarters · filed 2020-08-06 | $1.90M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $2.16M 10-Q · filed 2020-05-08 | $2.05M derived: sum of 2 quarters · filed 2020-05-08 | $2.25M derived: sum of 3 quarters · filed 2020-05-08 | $2.00M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $88.00K derived: sum of 2 quarters · filed 2020-03-12 | -$166.00K derived: sum of 3 quarters · filed 2020-03-12 | -$520.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$56.00K derived: sum of 2 quarters · filed 2019-11-12 | -$410.00K 10-Q · filed 2019-11-12 | -$521.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$254.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$608.00K 10-Q · filed 2019-08-08 | -$719.00K derived: sum of 3 quarters · filed 2019-08-08 | -$830.00K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$354.00K 10-Q · filed 2019-05-09 | -$465.00K derived: sum of 2 quarters · filed 2019-05-09 | -$576.00K derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$222.00K derived: sum of 2 quarters · filed 2019-03-12 | -$444.00K 10-K · filed 2019-03-12 | |
| 2017-09-30 | -$111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$333.00K 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | -$222.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |